What is X4 Pharmaceuticals, Inc. (XFOR) stock price today?

X4 Pharmaceuticals, Inc. (XFOR) is currently trading at $2.91, up 4.3% today.

What is XFOR P/E ratio?

X4 Pharmaceuticals, Inc.'s P/E ratio is -2.36. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is XFOR return on equity (ROE)?

X4 Pharmaceuticals, Inc.'s return on equity (ROE) is -63.05%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is X4 Pharmaceuticals, Inc.'s market cap?

X4 Pharmaceuticals, Inc. has a market capitalization of $274.47M.

NASDAQ · Biotechnology

X4 Pharmaceuticals, Inc. (XFOR) Stock

$2.91 +4.30% NASDAQ: XFOR Healthcare

Valuation

Metric	Value
Price	$2.91
Market Cap	$274.47M
P/E Ratio	-2.36
P/B Ratio	2.30
P/S Ratio	16.84
EPS (TTM)	$-1.87
52-Week High	$4.83
52-Week Low	$2.71
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-63.05%
ROA	-35.62%
ROCE	-37.61%
Gross Margin	-248.57%
Operating Margin	-248.57%
Net Margin	-568.80%
Debt/Equity	0.50
Current Ratio	10.08

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$3.0M	$35.0M
Operating Profit	$-75.0M	$-88.0M	$-108.0M	$-36.0M	$-87.0M
Net Profit	$-89.0M	$-94.0M	$-101.0M	$-37.0M	$-79.0M
EPS	$-119.58	$-45.60	$-17.07	$-5.59	$-1.87
Op Margin	—	—	—	-1423.6%	-247.4%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$117.0M	$156.0M	$147.0M	$146.0M	$290.0M
Total Liabilities	$53.0M	$82.0M	$96.0M	$124.0M	$104.0M
Cash	$82.0M	$122.0M	$99.0M	$56.0M	$217.0M
Borrowings	$40.0M	$38.0M	$58.0M	$78.0M	$77.0M

Latest News

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 7, 2026 X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors GlobeNewswire · Jul 1, 2026 X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference GlobeNewswire · May 27, 2026 How The X4 Pharmaceuticals (XFOR) Story Is Shifting With Mavorixafor And New EU Progress Simply Wall St. · May 21, 2026 Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now Zacks · May 20, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-71.0M	$-77.0M	$-97.0M	$-131.0M	$-86.0M
Investing Cash Flow	$-1.0M	$0	$-15.0M	$60.0M	$5.0M
Financing Cash Flow	$-2.0M	$-5.0M	$8.0M	$0	$0
Net Cash Flow	$3.0M	$40.0M	$-23.0M	$-44.0M	$161.0M
Free Cash Flow	$-72.0M	$-77.0M	$-97.0M	$-138.0M	$-89.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.01
EV / EBITDA	-1.87
FCF Yield	-31.37%
Quick Ratio	11.02
Interest Coverage	-10.06
Return 1Y	166.00%
Return 3Y	-92.44%
Return 5Y	-97.67%

Ownership

Insiders Held0.54%

Institutions Held100.42%

Institutions Float Held100.96%

Institutional Holder	Shares	Report Date
Morgan Stanley	9,466,992	2026-03-31
Empery Asset Management, LP	8,944,118	2026-03-31
FMR, LLC	8,103,400	2026-03-31
Bain Capital Life Sciences Investors, LLC	7,967,454	2026-03-31
Perceptive Advisors Llc	6,737,648	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ALGSAligos Therapeutics, Inc.	$5.34	+0.56%	-0.76	$33.05M	0.00%
FGENFibroGen, Inc.	$9.07	-1.63%	0.22	$36.69M	0.00%
INMBINmune Bio Inc.	$1.89	+3.28%	-2.81	$50.25M	0.00%
KPTIKaryopharm Therapeutics Inc.	$0.61	+0.83%	-0.03	$13.71M	0.00%
KZR	$7.29	+0.00%	-0.96	$53.86M	0.00%

About X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc. is led by CEO Adam R. Craig, employs 143 people, headquartered in US, publicly traded since 2017.

X4 Pharmaceuticals, Inc. (XFOR) stock trades at $2.91 with a market capitalization of $274.47M. The stock is valued at a price-to-earnings (P/E) ratio of -2.36, price-to-book of 2.30, price-to-sales of 16.84. Over the past 52 weeks the stock has ranged between $2.71 and $4.83, and currently trades 39.8% below its 52-week high.

On profitability, X4 Pharmaceuticals, Inc. generates a return on equity (ROE) of -63.05%, return on capital employed of -37.61%, an operating margin of -248.57%, a net profit margin of -568.80%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides